Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Front Oncol ; 11: 721659, 2021.
Article in English | MEDLINE | ID: mdl-34490120

ABSTRACT

Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to androgen deprivation therapy (ADT). Several molecular changes, particularly in the AR signaling cascade, have been described that may explain ADT resistance. The variety of changes may also explain why the response to novel therapies varies between patients. Testing the specific molecular changes may be a major step towards personalized treatment of CRPC patients. The aim of our study was to evaluate the molecular changes in the AR signaling cascade in CRPC patients. We have developed and validated several methods which are easy to use, and require little tissue material, for exploring AR signaling pathway changes simultaneously. We found that the AR signaling pathway is still active in the majority of our CRPC patients, due to molecular changes in AR signaling components. There was heterogeneity in the molecular changes observed, but we could classify the patients into 4 major subgroups which are: AR mutation, AR amplification, active intratumoral steroidogenesis, and combination of AR amplification and active intratumoral steroidogenesis. We suggest characterizing the AR signaling pathway in CRPC patients before beginning any new treatment, and a recent fresh tissue sample from the prostate or a metastatic site should be obtained for the purpose of this characterization.

2.
Mod Pathol ; 34(3): 660-671, 2021 03.
Article in English | MEDLINE | ID: mdl-32759979

ABSTRACT

The Gleason score is the most important prognostic marker for prostate cancer patients, but it suffers from significant observer variability. Artificial intelligence (AI) systems based on deep learning can achieve pathologist-level performance at Gleason grading. However, the performance of such systems can degrade in the presence of artifacts, foreign tissue, or other anomalies. Pathologists integrating their expertise with feedback from an AI system could result in a synergy that outperforms both the individual pathologist and the system. Despite the hype around AI assistance, existing literature on this topic within the pathology domain is limited. We investigated the value of AI assistance for grading prostate biopsies. A panel of 14 observers graded 160 biopsies with and without AI assistance. Using AI, the agreement of the panel with an expert reference standard increased significantly (quadratically weighted Cohen's kappa, 0.799 vs. 0.872; p = 0.019). On an external validation set of 87 cases, the panel showed a significant increase in agreement with a panel of international experts in prostate pathology (quadratically weighted Cohen's kappa, 0.733 vs. 0.786; p = 0.003). In both experiments, on a group-level, AI-assisted pathologists outperformed the unassisted pathologists and the standalone AI system. Our results show the potential of AI systems for Gleason grading, but more importantly, show the benefits of pathologist-AI synergy.


Subject(s)
Deep Learning , Diagnosis, Computer-Assisted , Image Interpretation, Computer-Assisted , Microscopy , Pathologists , Prostatic Neoplasms/pathology , Biopsy , Humans , Male , Neoplasm Grading , Observer Variation , Predictive Value of Tests , Reproducibility of Results
3.
Oncotarget ; 8(31): 51522-51529, 2017 Aug 01.
Article in English | MEDLINE | ID: mdl-28881664

ABSTRACT

OBJECTIVE: To validate previously discovered miRNAs (miR-31-5p and miR-149-5p) as prognostic factors for UTUC in an independent cohort of UTUC patients. PATIENTS AND METHODS: Multicenter, international and retrospective study of formalin-fixed paraffin-embedded tissue samples from 103 UTUC patients (45 progressing and 58 non-progressing) who underwent radical nephroureterectomy. Total RNA was isolated and reverse transcribed. The expression of target miRNAs (miR-31-5p and miR-149-5p) and the endogenous control miR-218-5p was evaluated in all samples by reverse transcription quantitative PCR. Normalized miRNA expression values were evaluated by multivariate forward stepwise Cox regression analysis. Kaplan Meier curves were used to discriminate between two groups of patients with a different probability of tumour progression. RESULTS: The mean age (range) of the series was 67 (33-94) years. Overall, 45 patients (43.7%) developed tumour progression and 32 patients (31.2%) died, 20 of these (62.5%) due to their UTUC, after a median follow-up of 36 months. The mean time for tumour progression and cancer-specific survival were 15 and 20 months, respectively. Five year tumour progression free survival and cancer-specific survival were 58% for ≤ pT2, 36% for pT3 and 0% for pT4 and 67.8% for ≤ pT2, 50.6% for pT3 and 0% for pT4, respectively. In the multivariate analysis, expression of miR-31-5p was found to be an independent prognostic factor of tumour progression (HR 1.1; 95% CI 1.039-1.273; p=0.02). Kaplan Meier curve shows that miR-31-5p expression values are able to discriminate between two groups of UTUC patients with a different probability of tumour progression (p=0.007). CONCLUSIONS: We have been able to validate our previous results in an independent multicentre international cohort of UTUC patients, suggesting that miRNA-31-5p could be a useful prognostic marker of UTUC progression. The application of miRNA expression values to clinical practice could refine the currently used clinicopathological-based approach for predicting UTUC patients' outcome.

4.
Mol Med ; 18: 1449-55, 2013 Jan 22.
Article in English | MEDLINE | ID: mdl-23196782

ABSTRACT

Current endocrine treatment for advanced prostate cancer does not result in a complete ablation of adrenal androgens. Adrenal androgens can be metabolized by prostate cancer cells, which is one of the mechanisms associated with progression to castration-resistant prostate cancer (CRPC). Aldo-keto reductase family 1 member C3 (AKR1C3) is a steroidogenic enzyme that plays a crucial role in the conversion of adrenal androgen dehydroepiandrosterone (DHEA) into high-affinity ligands for the androgen receptor (testosterone [T] and dihydrotestosterone [DHT]). The aim of this study was to examine whether AKR1C3 could be used as a marker and therapeutic target for CRPC. AKR1C3 mRNA and protein levels were upregulated in CRPC tissue, compared with benign prostate and primary prostate cancer tissue. High AKR1C3 levels were found only in a subset of CRPC patients. AKR1C3 can be used as a biomarker for active intratumoral steroidogenesis and can be measured in biopsy or transurethral resection of the prostate specimens. DuCaP (a CRPC cell line that has high AKR1C3 expression levels) used and converted DHEA under hormone-depleted conditions into T and DHT. The DHEA-induced growth of DuCaP could be antagonized by indomethacine, an inhibitor of AKR1C3. This study indicates that AKR1C3 can be considered a therapeutic target in a subgroup of patients with high AKR1C3 expression.


Subject(s)
3-Hydroxysteroid Dehydrogenases/metabolism , Biomarkers, Tumor/metabolism , Hydroxyprostaglandin Dehydrogenases/metabolism , Molecular Targeted Therapy , Orchiectomy , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/surgery , Aldo-Keto Reductase Family 1 Member C3 , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Dehydroepiandrosterone/pharmacology , Dihydrotestosterone/metabolism , Humans , Indomethacin/pharmacology , Male , Prostatic Neoplasms/pathology , Testosterone/metabolism
5.
Breast Cancer Res Treat ; 137(2): 609-16, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23239152

ABSTRACT

Many attempts have been made to combine the high diagnostic accuracy and conclusive rate of core needle biopsy (CNB) with the speed of fine needle aspiration cytology in evaluation of solid breast lesions. Multiple hybrid techniques have been developed to achieve this. We describe a cohort of patients for whom we used a relatively new, accelerated method of CNB processing, allowing for a definitive diagnosis the same day. All patients visiting the Radboud University Nijmegen Medical Centre breast clinic during a 4-year period were reviewed to identify all CNBs in this period performed in a same-day diagnosis track. CNB result was compared to post-operative pathology reports when available, and to follow-up when patients were not surgically treated. 1,060 patients underwent CNB of 1,383 lesions, 898 of which in a same-day diagnosis track with a sensitivity of 96.9 % and a specificity of 99.4 %. The inconclusive rate was 9.2 %. For a same-day diagnosis for solid breast lesions, we could give a conclusive diagnosis with accelerated CNB processing in 65 % of our patients requiring CNB. This technique can be used reliably in a same-day diagnosis breast clinic with a very high sensitivity, specificity, and conclusive rate.


Subject(s)
Biopsy, Large-Core Needle , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Female , Follow-Up Studies , Humans , Prospective Studies , Sensitivity and Specificity , Time Factors , Ultrasonography, Interventional/methods
6.
Clin Neurol Neurosurg ; 109(6): 520-2, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17462817

ABSTRACT

Prostate cancer can be complicated by spontaneous intracranial haematoma. In the acute setting, an intracranial haematoma can appear isodense on CT scanning, especially if a coagulopathy is present. Diffuse intravascular coagulation (DIC) can be the underlying pathophysiological mechanism that leads to spontaneous bleeding. It is important to recognize the possibility of DIC in cancer patients, since it has important therapeutical implications that may be life saving.


Subject(s)
Bone Neoplasms/secondary , Cerebral Hemorrhage/etiology , Disseminated Intravascular Coagulation/complications , Hematoma/etiology , Prostatic Neoplasms/complications , Aged , Bone Neoplasms/complications , Bone Neoplasms/pathology , Brain/pathology , Cerebral Hemorrhage/pathology , Diagnosis, Differential , Disseminated Intravascular Coagulation/pathology , Dominance, Cerebral/physiology , Facial Paralysis/etiology , Facial Paralysis/pathology , Fatal Outcome , Hematoma/pathology , Hemiplegia/etiology , Hemiplegia/pathology , Humans , Male , Neurologic Examination , Prostatic Neoplasms/pathology , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...